Published on 22/12/2025
Bioequivalence and Local Study Requirements in Vietnam in 2025
Step 1: Understanding the Regulatory Framework in Vietnam
Before embarking on the process of bioequivalence studies and local study requirements for drug registration in Vietnam, it is vital to comprehend the regulatory landscape governed by the Drug Administration of Vietnam (DAV). The DAV operates under the Ministry of Health (MoH) and oversees all drug registration activities and market authorization processes. Familiarizing yourself with the fundamental regulations, guidelines, and industry best practices is critical for ensuring compliance.
The key documents regulating drug registration in Vietnam include the Pharmaceutical Law (2016), guiding the registration process for pharmaceuticals, and subsequent decrees and circulars from the MoH. It is beneficial to keep abreast of any updates or amendments to these documents, as they may impact the registration process.
One must also recognize that the regulatory environment is increasingly aligned with international standards, especially those set forth by the International Conference
Step 2: Engaging a Vietnam DAV Drug Registration Consultant
Engagement of a Vietnam DAV drug registration consultant can be pivotal in navigating the complexities of the drug registration process. A knowledgeable consultant will provide insights into local regulatory expectations, help design a comprehensive strategy for bioequivalence studies, and assist in developing appropriate clinical trial protocols.
Selecting the right consultant involves assessing their experience with Vietnam’s regulatory affairs, specifically in handling drug registration and bioequivalence studies. It is advisable to review their track record, including successful submissions and any relevant case studies. Conducting interviews can also clarify their understanding of local regulations, language proficiency, and their approach to client collaboration.
After selecting a consultant, a clear contractual agreement should outline the scope of services, timelines, and fee structures. This contract will help establish transparent communication channels and ensure all parties have aligned expectations regarding responsibilities.
Step 3: Preparing the Bioequivalence Study Protocol
The bioequivalence study protocol is a foundational document that must be methodically developed to support the drug registration application. This protocol outlines the study design, objective, methodology, statistical considerations, and ethical issues. It must comply with ICH-GCP principles as well as the local guidelines set forth by the DAV.
In crafting this protocol, it is necessary to clearly state the drug formulation being tested and the reference product. The bioequivalence study should be designed to compare the pharmacokinetic (PK) properties of the test and reference medicines, demonstrating that they are interchangeable in clinical practice.
- Design Considerations: Choose an appropriate study design (e.g., single-dose, crossover) based on the drug’s characteristics and the target population.
- Sample Size Calculation: Properly justify the sample size used in the study, taking into account variability and the desired power of the study.
- Ethical Approval: Secure Institutional Review Board (IRB) approval prior to commencing the study, ensuring the rights and safety of participants are prioritized.
- Study Conduct: Execute the study according to the protocol while maintaining stringent adherence to GCP standards.
Having an approved bioequivalence study protocol is essential for the successful execution and subsequent submission for registration.
Step 4: Conducting the Bioequivalence Study
The bioequivalence study should adhere to the approved protocol while ensuring rigorous adherence to all ethical, scientific, and regulatory standards. This phase involves actively managing the study participant recruitment, administration of treatments, and collection of biological samples.
During the conduct of the study, it is essential to document every detail meticulously. This includes monitoring participant reactions, managing any adverse events, and ensuring compliance with study protocols. Having a detailed electronic data capture (EDC) system can enhance the accuracy and efficiency of data collection.
Post completion of the study, the analysis of the data must be conducted by qualified biostatisticians. The statistical analysis should aim to demonstrate that the 90% confidence intervals for the ratios of the area under the curve (AUC) and maximum concentration (Cmax) fall within the acceptable range, typically 80% to 125%, as prescribed by the DAV.
Step 5: Compiling the Dossier for Submission
Following the successful completion of the bioequivalence study, the next step involves preparing the regulatory submission dossier. The dossier must be comprehensive and contain all requisite documents to satisfy the DAV’s requirements for drug registration.
The dossier typically includes, but is not limited to:
- Administrative documents such as application forms and authorized signatures.
- The complete bioequivalence study report, including raw data, statistical analysis, and summary conclusions.
- Product information and labeling, which must comply with Vietnamese regulations concerning product claims and usage instructions.
- Manufacturing information, including batch records and quality control procedures that demonstrate consistency in product quality.
- Pharmacological and toxicological information necessary to support the product’s safety profile.
Every document must maintain clarity and consistency, presented in both Vietnamese and English as necessary. Additionally, completeness checks should be instituted to ensure no critical components are omitted before the final submission.
Step 6: Submission and Review Process
Once the submission dossier is completed and double-checked for accuracy, it can be submitted to the DAV. The submission must be made through the DAV’s approved channels, conforming to any specific submission guidelines. It is common to submit the application both electronically and in hard copy.
After submission, the application will enter the review stage, during which DAV assessors will evaluate the documents for compliance with regulatory requirements. The review timeline can vary based on the complexity of the submission. Applicants should maintain open lines of communication with the regulatory body, providing any additional information requested promptly.
It is critical to understand that delays can occur, often due to missing information or adverse feedback on the bioequivalence study results. Should this happen, the applicant is expected to address the issues raised efficiently.
Step 7: Post-Approval Commitments and Market Authorization
Upon successful completion of the review process and receiving market authorization, drug sponsors must fulfill any post-approval commitments as stipulated by the DAV. These may include continued pharmacovigilance studies, mandatory reporting of adverse drug reactions, and ensuring compliance with Good Manufacturing Practices (GMP).
Regular renewal submissions may be required to maintain market authorization status, typically occurring every five years. Companies should ensure to stay updated on regulatory changes that may affect their product status or the requirements for market re-registration.
Maintaining compliance with ongoing vigilance and rigorous documentation practices is essential to uphold the integrity of the drug product and trust with both healthcare professionals and regulatory authorities.